secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001628280-23-036386
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M
-----------------------------------------------------------------------

- Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.
- FDA agreed on ORR as interim endpoint for accelerated approval; Phase 3 registrational trial planned contingent on CRDF-004.
- mPDAC CRDF-001: ORR 19% (4/21 evaluable) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo for SoC alone.
- Phase 2 SCLC monotherapy cleared to continue enrollment after safety review of first six patients.
- Cash, equivalents, and short-term investments $81.4M; net cash burn Q3 $8.0M; runway into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/0001628280-23-036386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/crdf-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer